Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial

Patrick Durez¹ · Karel Pavelka² · Maria Alicia Lazaro³ · Abraham Garcia-Kutzbach⁴ · Robert J. Moots⁵ · Howard Amital⁶ · Marinella Govoni⁷ · Nathan Vastesaeger⁸

Published online: 12 May 2018

© International League of Associations for Rheumatology (ILAR) 2018

Correction to: Clinical Rheumatology (2018) 37:1417–1420
<https://doi.org/10.1007/s10067-018-4074-6>

The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

The first is in “Results”, “Efficacy”, where the rate of remission at 6 months is listed twice for South Africa. The second listing is incorrect and should be removed, leaving the “Efficacy” section to read:

Rates of remission at 6 months, defined as a DAS28-ESR <2.6, varied by region. Remission rates were highest in

South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Rates of remission were generally highest in regions with the lowest baseline disease activity (i.e., with the highest rates of moderate disease activity) (Fig. 1). An exception to this was South Africa, which had a high rate of high disease activity at baseline and the highest remission rate.

Secondly, the original presentation of Table 1 contained errors in the “Europe”, “Middle East”, “South Africa”, and “Asia” columns in the rows falling under the following row headings: “Concomitant MTX, *n* (%)”, and “Concomitant csDMARD combinations^c, *n* (%)”. Table 1 has been corrected and is presented as follows:

The online version of the original article can be found at <https://doi.org/10.1007/s10067-018-4074-6>

✉ Patrick Durez
patrick.durez@uclouvain.be

¹ Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Durez Avenue Hippocrate 10, B-1200 Brussels, Belgium

² Institute of Rheumatology (Revmatologicky Ustav), Na Slupi 4, 128 50 Praha 2, Czech Republic

³ Instituto de Rehabilitacion Psicofisica de la Ciudad de Buenos Aires, Echeverria 955, C1428DQG Buenos Aires, Argentina

⁴ AGAR, UFM, 6 Avenida 7-55, zona 10, 01010 Guatemala City, Guatemala

⁵ University Hospital Aintree, Longmoor Ln, Liverpool L9 7AL, UK

⁶ Sheba Medical Center-Tel-Hashomer, Emek HaEla St 1, Ramat Gan, Israel

⁷ MSD, Via Vitorchiano, 151, 00189 Rome, RM, Italy

⁸ MSD, Clos du Lynx 5, 1200 Woluwe-Saint-Lambert, Belgium

Table 1 Baseline patient characteristics, disease activity, and concomitant therapies by region

Parameter	Europe (<i>N</i> = 1818)	Canada (<i>N</i> = 218)	Middle East (<i>N</i> = 88)	Latin America (<i>N</i> = 906)	South Africa (<i>N</i> = 117)	Asia (<i>N</i> = 133)
Female, <i>n</i> (%)	1439 (79.2)	166 (76.1)	73 (83.0)	826 (91.2)	95 (81.2)	117 (88.0)
Age (y), mean ± SD [range]	54.1 ± 12.6 [18–84]	56.0 ± 11.9 [23–84]	48.3 ± 13.1 [20–74]	49.3 ± 12.3 [18–88]	50.1 ± 14.1 [23–80]	45.4 ± 12.2 [23–74]
Smoking history, <i>n</i> (%)						
Nonsmoker	977 (53.7)	71 (32.6)	51 (58.0)	660 (72.8)	78 (66.7)	126 (64.7)
Current smoker	454 (25.0)	60 (27.5)	24 (12.6)	114 (12.6)	24 (20.5)	3 (2.3)
Prior smoker	387 (21.3)	87 (39.9)	13 (14.8)	132 (14.6)	15 (1.8)	4 (3.0)
EULAR disease activity, <i>n</i> (%)						
Moderate ^a	525 (29.0)	50 (23.0)	19 (21.8)	84 (9.3)	10 (8.5)	10 (7.5)
High ^b	1286 (71.0)	167 (77.0)	68 (78.2)	821 (90.7)	107 (91.5)	123 (92.5)
DAS28-ESR, mean ± SD	5.7 ± 1.0	5.9 ± 1.1	6.0 ± 1.0	6.4 ± 1.0	6.7 ± 1.1	6.2 ± 0.9
DAS28-CRP, mean ± SD	5.2 ± 1.0	5.5 ± 1.0	5.4 ± 0.9	5.8 ± 1.0	5.8 ± 1.0	5.4 ± 0.9
Disease duration (y), mean ± SD	7.5 ± 7.8	6.6 ± 8.4	6.9 ± 7.0	8.6 ± 8.2	7.6 ± 7.9	5.4 ± 4.8
TJC28, mean ± SD	11.6 ± 6.5	14.5 ± 7.5	12.6 ± 6.3	15.1 ± 6.1	15.3 ± 6.6	12.7 ± 6.1
SJC28, mean ± SD	8.3 ± 5.1	10.5 ± 4.7	7.5 ± 4.6	11.8 ± 5.7	14.1 ± 6.1	8.4 ± 4.4
CRP (mg/L), median [IQR]	6.4 [2.2–15.5]	4.4 [1.8–9.4]	9.9 [4.9–21.7]	9.6 [3.9–23.4]	6.7 [2.5–18.3]	10.0 [4.2–20.7]
Rheumatoid factor (IU/mL), median (IQR)	51 (15–164)	18 (15–130)	58 (15–160)	165 (45–438)	78 (15–213)	93 (24–210)
Anti-CCP antibody (U/mL), median (IQR)	136 (16–495)	19 (16–254)	62 (16–500)	256 (77–571)	120 (16–468)	300 (41–500)
Concomitant MTX, <i>n</i> (%)						
< 10 mg/week	81 (4.5)	4 (1.8)	2 (2.3)	53 (5.8)	0 (0.0)	3 (2.3)
≥ 10 and < 15 mg/week	270 (14.9)	12 (5.5)	25 (28.4)	194 (21.4)	11 (9.4)	12 (9.0)
≥ 15 mg/week	1050 (57.8)	174 (79.8)	45 (51.1)	519 (57.3)	93 (79.5)	117 (88.0)
Did not use MTX	417 (22.9)	28 (12.8)	16 (18.2)	140 (15.5)	13 (11.1)	1 (0.8)
Concomitant csDMARD combinations ^c , <i>n</i> (%)						
MTX only	1014 (56.1)	86 (39.4)	38 (43.2)	462 (51.0)	51 (43.6)	29 (21.8)
MTX + chloroquine derivatives	123 (6.8)	69 (31.7)	14 (15.9)	139 (15.4)	15 (12.8)	74 (55.6)
MTX + leflunomide	100 (5.5)	21 (9.6)	9 (10.2)	72 (8.0)	11 (9.4)	4 (3.0)
MTX + sulfasalazine	92 (5.1)	4 (1.8)	1 (1.1)	39 (4.3)	11 (9.4)	4 (3.0)
MTX + chloroquine derivatives + sulfasalazine	57 (3.2)	0 (0.0)	5 (5.7)	19 (2.1)	11 (9.4)	14 (10.5)
Leflunomide only	227 (12.5)	6 (2.8)	5 (5.7)	60 (6.6)	4 (3.4)	0 (0.0)
Concomitant corticosteroids	1079 (59.4)	95 (43.6)	59 (67.0)	681 (75.2)	66 (56.4)	104 (78.2)

CCP cyclic citrullinated peptide, DAS28-CRP 28-joint DAS based on CRP, DAS28-ESR 28-joint DAS based on ESR, IQR interquartile range, IU international units, SJC28 swollen joint count based on 28 joints, TJC28 tender joint count based on 28 joints, U units.

^a DAS28-ESR = 3.2–5.1

^b DAS28-ESR > 5.1

^c Only the six combinations most commonly used by the efficacy-evaluable population for all regions combined are listed. All other combinations were used by <3% of the total efficacy-evaluable population